A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 Ibrutinib for Treatment of Relapsed Hairy Cell Leukemia
MD Anderson Study Status
This phase II trial studies how well ibrutinib works in treating patients with hairy cell leukemia that has returned after a period of improvement. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Hairy Cell Leukemia, Hairy Cell Leukemia Variant
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.